预约演示

更新于：2025-05-07

Postpartum Hemorrhage

产后出血

更新于：2025-05-07

基本信息

别名

BLEEDING POSTPARTUM、Bleeding post-delivery、Bleeding postpartum

+ [56]

简介

Excess blood loss from uterine bleeding associated with OBSTETRIC LABOR or CHILDBIRTH. It is defined as blood loss greater than 500 ml or of the amount that adversely affects the maternal physiology, such as BLOOD PRESSURE and HEMATOCRIT. Postpartum hemorrhage is divided into two categories, immediate (within first 24 hours after birth) or delayed (after 24 hours postpartum).

关联

项与产后出血相关的药物

Ferric Derisomaltose

异麦芽糖酐铁

靶点-

作用机制

铁调节

在研机构

Nippon Shinyaku Co., Ltd. [+2]

原研机构

Pharmacosmos A/S

在研适应症

铁缺乏 [+4]

非在研适应症

晚期恶性实体瘤 [+10]

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期2017-12-04

Carbetocin

卡贝缩宫素

靶点

OXTR

作用机制

OXTR激动剂

在研机构

ACADIA Pharmaceuticals, Inc. [+2]

原研机构

Ferring BV

在研适应症

出血 [+4]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期2015-04-17

Fibrinogen Concentrate (Human)

靶点

Fibrinogen

作用机制

纤维蛋白原刺激剂

在研机构

CSL Behring GmbH

原研机构

ProMetic Biotherapeutics Ltd.

在研适应症

出血

非在研适应症

获得性纤维蛋白原缺乏 [+6]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2009-01-16

680

项与产后出血相关的临床试验

NCT05977686

/ Not yet recruitingN/AIIT

Point-of-Care Hemoglobin Testing in Pregnant Patients

The project is a prospective observational study aimed to assess and to validate the use of point-of-care hemoglobin testing in pregnancy. Point-of-care hemoglobin testing has the potential to (1) increase access to hemoglobin monitoring in pregnancy in low resource settings, (2) increase availability of hemoglobin monitoring in anemic patients, and (3) provide immediate results for real-time patient counseling and intervention. However, to date, point-of-care hemoglobin testing devices have not yet been studied for use in an ambulatory obstetric population. The Masimo device is a Root Radical 7 Pulse CO-Oximeter, manufactured by Masimo, Inc. This device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value. The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement. Participants in this study will be approached at the Obstetrics and Gynecology clinics at George Washington Medical Faculty Associates. Point-of-care hemoglobin measurements will be assessed using the non-invasive Masimo device along with minimally-invasive hemoglobin HemoCue® Hb 801 device and compared to traditional venipuncture hemoglobin testing.

开始日期2025-10-01

申办/合作机构-

NCT06843265

/ Not yet recruitingN/AIIT

Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region: a Cohort Study

This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths. This condition presents a higher risk in low- and middle-income countries (LMICs), particularly where access to quality care is limited. Recognizing the urgency of addressing this public health problem, the Colombian Ministry of Health and Social Protection has implemented the Maternal Mortality Reduction Acceleration Plan (PARE) to improve maternal mortality indicators and meet the Sustainable Development Goals (SDGs).
The project will evaluate the results and perception of a new device in the management of stage II PPH in referral hospitals in the department of Valle del Cauca, integrated in the Hospital Padrino strategy. This initiative seeks not only to improve the understanding and treatment of PPH, but also to strengthen institutional capacities through education, creation of telecare networks and care services adapted to local needs.

开始日期2025-06-01

申办/合作机构

Hospital Universitario del Valle Evaristo Garcia

NCT06897371

/ Not yet recruitingN/AIIT

Effect of Postpartum Hemorrhage Management Education Given with Kahoot Method on Knowledge, Self-Confidence in Intervention and Motivation Levels of Midwifery Students

This study was planned to investigate the effect of postpartum hemorrhage management training given with the Kahoot method on the knowledge, self-confidence in intervention and motivation levels of midwifery students. The research population will consist of third-year students studying at the Department of Midwifery, Hamidiye Faculty of Health Sciences (HSBF), Health Sciences University (SBU) in the spring semester of the 2024-2025 academic year (N: 80). In this semi-experimental pre-test and post-test design and control group planned study, in order to determine the sample size; the data were normally distributed, the standard deviation of the main mass was estimated as 1 and the effect size (effect size, difference) was estimated as 0.8. For the analysis to be conducted, it was calculated that the highest power value of the study would be 0.942182 if two independent n₁=40, n₂=40 samples were taken at a significance level of 5%. In addition, the adequacy of the sample size in the study will be evaluated with post hoc power analysis after the data are collected.
Students who volunteer to participate in the study will be assigned to the intervention and control groups using the computer-aided simple random sampling method. Computer-aided randomization will be used in the study, and the number of cases will be entered through the program with the URL address https://www.randomizer.org and random assignment will be made to the intervention and control groups. Before the data collection forms begin training, the "Informed Voluntary Consent Form" will be shared with the students participating in the study and their approval will be requested. The "Introductory Information Form", "Postpartum Hemorrhage Management Information Form", "Self-Confidence/Competence Scale in Patient Intervention" and "Motivation Scale Regarding the Teaching Material" will be applied to the students who agree to participate in the study.

开始日期2025-05-05

申办/合作机构-

100 项与产后出血相关的临床结果

登录后查看更多信息

100 项与产后出血相关的转化医学

登录后查看更多信息

0 项与产后出血相关的专利（医药）

登录后查看更多信息

10,976

项与产后出血相关的文献（医药）

2025-12-31·Journal of Obstetrics and Gynaecology

Enhancing postpartum haemorrhage training by integrating case-problem based learning with simulation: a quasi-experimental study [Letter]

Article

作者: Ismath, Mohammed ; Triwiyanto, Triwiyanto ; Luthfiyah, Sari

2025-12-31·The Journal of Maternal-Fetal & Neonatal Medicine

Subsequent pregnancy outcomes following conservative management for placenta accreta spectrum disorders: an ambispective cohort study

Article

作者: Long, Yu ; Huang, Yan ; Ma, Youliang ; Chen, Kai ; Bai, Yulu ; Chen, Junyao ; Yang, Fang

BACKGROUNDPlacenta accreta spectrum disorders (PAS), a devastating obstetric complication, has increased dramatically in recent decades along with the growing rate of cesarean worldwide. Various conservative management techniques, aimed to avoid hysterectomy and potentially preserve fertility, have been implemented in the management of PAS. However, reports on subsequent pregnancy outcomes following conservative management for PAS are limited.OBJECTIVETo systematically evaluate the subsequent pregnancy outcomes in PAS patients undergoing conservative management.METHODSThis was a single-center, ambispective cohort study conducted between January 2013 to March 2021. Follow-ups were conducted annually, extending until March 2023. Eligible patients were PAS patients who underwent successful conservative treatment and had intentions for future fertility. Baseline characteristics, conservative management strategies, and subsequent pregnancy outcomes were collected and analyzed. Primary outcome was the subsequent pregnancy outcomes, including interpregnancy interval, conceive method, pregnancy success rate, pregnancy and delivery outcomes, and major maternal morbidities.RESULTSA total of 40 patients with conservatively managed PAS and attempting subsequent pregnancies were included. These patients were further divided into the subsequent pregnancy group (n = 28) and non-pregnancy group (n = 12). There were no significant differences in term of baseline characteristics, conservative management, and delivery outcome between the two groups(All p < 0.05). The menstrual resumption time was 4.5 (2.25-6.00) months, and the interpregnancy interval was 39.7 ± 26.4 months. In the subsequent pregnancy, 28 patients experienced at least one pregnancy, with a total of 43 subsequent pregnancies. Ultimately, 60% (24/40) of patients successfully delivered but with a PAS recurrence of 33.3% (8/24). Major maternal morbidity included postpartum hemorrhage (PPH) (25%), disseminated intravascular coagulation (12.5%), uterine rupture (4.2%) and hysterectomy (4.2%). Furthermore, the incidence of composite adverse delivery outcomes was 45.8% (11/24). Neonatal outcomes were generally favorable, with a full-term birth rate of 87.5% and live birth rate of 95.8% (23/24).CONCLUSIONOur findings reveal that while conservative management for PAS does not compromise subsequent fertility, it does pose substantial risks in subsequent pregnancies, including high recurrence rates of PAS, significant PPH, and increased incidence of composite adverse delivery outcomes. Patients should be thoroughly informed of the related risks and subsequent pregnancies necessitate comprehensive preconception counseling, meticulous antenatal care and individualized management strategies to minimize these risks.

2025-12-31·The Journal of Maternal-Fetal & Neonatal Medicine

Risk factors for emergency department visits and readmissions for postpartum hypertension

Article

作者: Murphy, Aisling ; Alexander, Sabrina ; Muñoz, Hector E. ; Mei, Jenny Y.

OBJECTIVEPostpartum hypertension accounts for 15 to 20% of postpartum Emergency Department (ED) visits and readmissions in the United States. Postpartum readmission is a quality metric and target of quality improvement as it indicates poor control of hypertension and can portend increased morbidity. We aim to evaluate risk factors for postpartum ED visits and readmissions for hypertension.METHODSThis was a retrospective cohort study of all birthing patients with peripartum hypertension at a single tertiary care center over a 5-year period (2017-2022). Inclusion criteria were age 18 years or above, existing diagnosis of chronic hypertension or hypertensive disease of pregnancy diagnosed during the intrapartum or postpartum course, and both delivery and ED visit or readmission at the study institution. Maternal baseline and intrapartum characteristics were chart abstracted. Primary outcome was ED visit or readmission (EDR) for postpartum hypertension. Patients who had EDR within 42 days of delivery were compared to those who underwent routine outpatient surveillance. For all analyses, p values were two-way, and the level of statistical significance was set at p < 0.05.RESULTSOf 16,162 patients who gave birth during the study period, 2403 (14.9%) patients met the definition of peripartum hypertension. 218 (9.1%) presented to the ED or were readmitted for hypertension. Risk factors for EDR were as follows: maternal age ≥40 years (22.9% vs 15.3%, p = 0.003), prenatal aspirin use (6.9% vs 3.9%, p = 0.039), cesarean delivery (42.7% vs 35.8%, p = 0.044), chronic hypertension (37.2% vs 31.6%, p = 0.029), preeclampsia with severe features (32.6% vs 15.6%, p < 0.001), postpartum hemorrhage (22.9% vs 12.0%, p < 0.001), and intrapartum need for intravenous anti-hypertensives (23.9% vs 3.3%, p < 0.001). Factors at discharge that increased risk of EDR included prescription of anti-hypertensives at discharge (27.5% vs 8.6%, p < 0.001) and having >50% elevated blood pressures within the 24 h prior to discharge (16.5% vs 11.9%, p = 0.046). In a multivariable logistic regression controlling for prenatal aspirin use, mode of delivery, postpartum hemorrhage, and chorioamnionitis, a higher risk of EDR remained for maternal age ≥40 years (aOR, 1.56; 95% confidence interval (CI), 1.11-2.20; p = 0.011), PO anti-hypertensives at discharge (aOR, 4.05; 95% CI, 2.86-5.73; p < 0.001), preeclampsia with severe features (aOR, 2.50; 95% CI, 1.83-3.42; p < 0.001), and history of IV anti-hypertensive exposure (aOR, 9.30; 95% CI, 6.20-13.95; p < 0.001).CONCLUSIONSMaternal age of 40 years and above, chronic hypertension, preeclampsia with severe features, prescription of anti-hypertensives on discharge, and elevated blood pressures leading up to discharge are associated with postpartum ED visits or readmissions for hypertension. Risk factor identification can aid in the development of predictive tools to determine high risk groups and interventions to reduce ED visits and readmissions.

项与产后出血相关的新闻（医药）

2025-04-23

·汇聚南药

14个中药品牌大卖超10亿！

根据数据统计，2024年在中国城市实体药店终端销售额超过10亿元的中成药品牌有14个。其中，华润三九的感冒灵颗粒和东阿阿胶的阿胶的销售额超过20亿元。　　数据显示，华润三九的感冒灵颗粒在2024年中国城市实体药店终端销售额达到25.9亿元，增长率为10.39%。该产品解热镇痛，用于感冒引起的头痛，发热，鼻塞，流涕，咽痛。据悉，该品牌2019-2020年销售额均达到20亿元以上，2021年急跌后在2022年起恢复高速增长态势。　　华润三九在2024年年报中表示，公司持续强化感冒、皮肤、胃肠品类组合，打造全病程管理和多方位解决方案。其中，999感冒灵在消费者与渠道端进行大渗透，抢占消费者心智，增长快速且地位稳固。东阿阿胶的阿胶具有补血、止血、养血、滋阴燥热、抗疲劳、美容养颜、改善睡眠等功效和作用。同时还具有提高免疫力、增强体质、促进造血、降低血液粘稠度等功效和作用。阿胶可用于治疗血虚证，出血证，肺阴虚燥咳，心烦失眠，热病伤阴等，比如贫血、便血、产后出血、心悸、眩晕、月经不调等。　　此外，根据梳理，2024年在中国城市实体药店终端销售额超过10亿元的中成药品牌，包括：太极集团重庆涪陵制药的藿香正气口服液、漳州片仔癀药业的片仔癀、江中药业的健胃消食片、东阿阿胶的复方阿胶浆、山东福牌阿胶的阿胶、北京同仁堂股份同仁堂制药的安宫牛黄丸、江西康恩贝中药的肠炎宁片、太极集团重庆涪陵制药的急支糖浆、扬子江江苏龙凤堂中药的蓝芩口服液、云南白药集团的云南白药气雾剂等12个品牌。　　其中云南白药气雾剂在2024年中国城市实体药店终端销售额增长率为14.03%，头次突破10亿元。资料显示，云南白药气雾剂是独家产品，用于跌打损伤，瘀血肿痛，肌肉酸痛及风湿疼痛。该产品2015-2021年的销售额保持在5亿元水平，2022年起呈现高速增长态势。片仔癀是中国现存历史悠久的名贵中成药，主治是清热解毒，凉血化瘀，消肿止痛，用于痈疽疔疮，无名肿毒，跌打损伤，烫烧伤等各种炎症。据悉，近年来，中医药振兴发展迎来天时地利人和的大好时机，片仔癀公司也把握时代脉搏，奔跑在变革与创新的道路上，不断加大研发投入，深度挖掘中医药健康产业的无限潜力，致力于打造中医药行业的亮丽名片。太极集团重庆涪陵制药的藿香正气口服液解表化湿，理气和中，用于外感风寒、内伤湿滞或夏伤暑湿所致的感冒，症见头痛昏重、胸膈痞闷、脘腹胀痛、呕吐泄泻；胃肠型感冒见上述证候者。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~免责声明“汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：制药网往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

核酸药物

2025-02-14

·医脉通

《母婴呼吸道合胞病毒感染预防指南（2025年版）》发布！近期更新重点指南一览~

经常错过自己最关注的指南上新内容？想要及时接收到指南上新提醒？临床指南APP——微信绑定功能即可满足~ TIPS：首次完成绑定还可得3天临床指南VIP！ > 具体方法本周热门指南推荐直接点击即可阅读母婴呼吸道合胞病毒感染预防指南（2025年版）本指南针对8个临床问题形成了15条推荐意见，涵盖了母婴人群预防吸道合胞病毒（RSV）感染的非药物预防、药物预防和疫苗预防措施等内容，旨在全面提升此类高风险人群的RSV感染防控水平。直接点击即可阅读孕产妇围分娩期预防性使用抗菌药物的专家共识本文共形成了13条共识意见，涉及经阴道分娩、剖宫产术分娩以及有相关并发症/合并症（如肥胖、糖代谢异常、合并自身免疫性疾病等）的孕产妇在分娩前、分娩中及分娩后预防性使用抗菌药物的方案。直接点击即可阅读阿尔茨海默病药物治疗指南本文内容涵盖了阿尔茨海默病治疗原则，对症治疗药物中的胆碱酯酶抑制剂、兴奋性氨基酸受体拮抗剂、精神行为症状的药物治疗方法，Aducanumab、Lecanemab 和Donanemab 疾病修饰治疗，甘露特纳的使用，以及中医药物治疗原则和方法。直接点击即可阅读指导肾性贫血患者自我管理的中国专家共识（2024版）本共识内容包括为患者评估并建立必备的知识储备、及时就诊及随访、合理用药、生活方式指导、监测并避免加重因素、医患共同决策和自我管理评估，多维度系统规范化指导肾性贫血患者自我管理。直接点击即可阅读成人脓毒症患者β-内酰胺类抗生素延长输注专家共识 β-内酰胺类抗生素延长输注时间是一种简便有效的优化药物PK/PD，提高药物治疗效果的方法。本共识就成人脓毒症患者β- 内酰胺类抗生素延长输注时间的基础理论、有效性、安全性及临床使用要点展开讨论，总结现有的循证医学证据，以供临床实践参考。直接点击即可阅读餐后低血压管理的中国专家共识本共识内容包括了餐后低血压（PPH）的诊断、评估体系、管理流程及药物选择,以指导心内科医生优化PPH的管理,最大程度改善患者预后。直接点击即可阅读代谢性心血管疾病基层综合防控专家共识本文旨在旨在规范基层医疗机构对CMD的综合诊疗行为，包括危险评估、早期诊断、代谢控制、分级转诊和全病程管理等内容，实现CMD防控关口前移，以降低ASCVD事件发生。直接点击即可阅读 2025 CVIT临床专家共识：血管内超声检查血管内超声（IVUS）检查可提供精确的冠状动脉解剖信息，包括定量测量和形态学评估。本文主要总结了IVUS图像的测量和评估方法以及IVUS在经皮冠状动脉中使用的临床证据。直接点击即可阅读复杂剖宫产手术专家共识（2024）本文结合我国的具体情况，对复杂剖宫产术的定义、医学范畴等给出推荐意见，以期为规范管理提供指导。直接点击即可阅读 2024 KSE指南：子宫内膜异位症的临床评估和管理本文是对2018年子宫内膜异位症指南的更新，主要内容涉及子宫内膜异位症的诊断、医学和外科管理、特殊人群的考虑因素及其与癌症的复杂关系等关键领域。直接点击即可阅读非结核分枝杆菌肺病与支气管扩张症复合病的诊断与治疗专家共识本共识提出了10个核心问题，内容涵盖病因学检查、诊断、治疗、预后转归及管理等方面，最终形成了14条推荐意见。直接点击即可阅读小肠克罗恩病的内镜诊治共识（2024，上海）本共识基于循证医学依据及专家经验，聚焦小肠克罗恩病的流行病学、内镜及影像学诊断、小肠镜治疗、药物治疗及随访等临床问题，形成相关推荐意见，以便规范小肠克罗恩病诊治流程，改善患者预后。临床指南app-医问答临床指南app7.3及之后版本新增医问答板块，汇聚临床专业问答知识，扫描下方二维码进入临床指南app，按如下步骤操作，即可参与学习~ 点点击“阅读原文”，即可查看相关指南内容~

疫苗临床研究

2025-01-15

·access wire

CB Therapeutics Breaks Ground on Sustainable Ergoline Biosynthesis Through Precision Fermentation

CARLSBAD, CA / ACCESSWIRE / January 15, 2025 / CB Therapeutics, a U.S.-based synthetic biology company known for its innovative bio-manufacturing solutions, today announced the expansion of its platform to include ergoline-based compounds. Ergolines-structurally related to alkaloids naturally found in ergot fungi-hold broad potential in areas ranging from neurological research and psychiatric applications to treatments for migraines, postpartum hemorrhage, and Parkinson\'s disease. Building on its proven precision fermentation platform, CB Therapeutics now offers a scalable, eco-conscious pathway for producing these high-value molecules with unmatched consistency and purity. While many recognize ergolines through their association with lysergic acid derivatives-including LSD-this diverse class of compounds has long been investigated for numerous medical and research applications. Traditional chemical synthesis methods or direct sourcing from ergot fungi can be dangerous, inefficient, environmentally burdensome, and difficult to standardize. By contrast, CB Therapeutics utilizes yeast-based precision fermentation to produce bioidentical ergoline compounds with minimal waste, reduced carbon footprint, and dependable yields at any scale.\"Our goal is to unlock nature\'s most promising compounds in the most sustainable way,\" said Sher Butt, MBA, Chief Executive Officer of CB Therapeutics. \"By adding ergolines to our synthetic biology platform, we\'re helping to accelerate research and commercialization pathways for partners who want to explore or develop new therapies in neurology, mental health, and beyond.\"\"Our precision fermentation platform can deliver consistent, pure compounds for use in translational research and product development. Our aim is to make these molecules more accessible and sustainable, ultimately broadening their potential impact.\" noted Jacob Vogan, PhD, Chief Scientific Officer at CB TherapeuticsKey Advantages of CB Therapeutics\' Biosynthesis Platform:Sustainable Production: Precision fermentation significantly reduces toxic byproducts and resource consumption compared to traditional extraction or chemical synthesis methods.Scalability & Consistency: From small research batches to large-scale manufacturing, the company\'s bioreactors and integrated processing systems ensure high quality precision fermentation batches.Broad Application Potential: Beyond psychedelic research (e.g., LSD derivatives), ergoline-related compounds show promise in treating migraines, supporting obstetric care, and exploring therapeutic avenues in neurology and psychiatry.Partnership Opportunities: CB Therapeutics actively seeks collaborations to accelerate product development in pharmaceuticals, clinical research, and other emerging markets worldwide.For more information on partnership, licensing, or collaboration inquiries, please contact [email protected]About CB TherapeuticsCB Therapeutics is a U.S.-based synthetic biology company focused on tackling humankind\'s critical challenges in mental health, physical wellness, food scarcity, and nutrition. Through a proprietary bio-manufacturing platform, CB Therapeutics harnesses yeast, precision fermentation, and advanced genetic engineering to produce high-value molecules sustainably and cost-effectively. The company\'s 16,000 sq. ft. fully licensed facility in Southern California boasts cutting-edge laboratories, robust bioreactor systems, data generation for AI training applications, and an extensive suite of analytical instruments-enabling the delivery of transformative solutions in psychedelics, cannabinoids, food technologies, and more.SOURCE: CB Therapeutics